Regeneron and Intellia Expand Their 2016 Collaboration to Develop CRISPR/CAS9 Based Therapies

 Regeneron and Intellia Expand Their 2016 Collaboration to Develop CRISPR/CAS9 Based Therapies

Regeneron and Intellia Expand Their 2016 Collaboration to Develop CRISPR/CAS9 Based Therapies

Shots:

  • Under the amended agreement, Intellia to receive ~$70M as up front with an additional equity investment of $30M at $32.42/ share. The 2016 collaboration get extended until April 2024 with Regeneron having an option to renew for an additional 2years
  • Regeneron will get rights to discover & develop CRISPR/Cas9-based therapies for an additional 5 in vivo liver targets, for a total of up to 15 targets. The companies will jointly research these in vivo targets, these targets may be developed by Regeneron or Intellia or co-developed under certain conditions
  • As per the 2016 agreement, Intellia will receive royalties and milestones for the in vivo products it independently develops while Regeneron will get a royalty-bearing non-exclusive license to certain Intellia’s IP to develop and commercialize up to 10 ex vivo CRISPR/Cas9 products in defined cell types.  Additionally, the two companies will co-develop potential products for the hemophilia A and B

Click here to read full press release/ article | Ref: Businesswire | Image: Regeneron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post